Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Malignant Melanoma

  Free Subscription

Articles published in J Immunol

Retrieve available abstracts of 28 articles:
HTML format

Single Articles

    March 2021
  1. SINGH S, Xiao Z, Bavisi K, Roszik J, et al
    IL-1alpha Mediates Innate and Acquired Resistance to Immunotherapy in Melanoma.
    J Immunol. 2021 Mar 15. pii: jimmunol.2000523. doi: 10.4049/jimmunol.2000523.
    PubMed     Abstract available

    January 2021
  2. O'CONNELL P, Hyslop S, Blake MK, Godbehere S, et al
    SLAMF7 Signaling Reprograms T Cells toward Exhaustion in the Tumor Microenvironment.
    J Immunol. 2021;206:193-205.
    PubMed     Abstract available

    October 2020
  3. OBA T, Hoki T, Yamauchi T, Keler T, et al
    A Critical Role of CD40 and CD70 Signaling in Conventional Type 1 Dendritic Cells in Expansion and Antitumor Efficacy of Adoptively Transferred Tumor-Specific T Cells.
    J Immunol. 2020;205:1867-1877.
    PubMed     Abstract available

    July 2020
  4. TUCKER CG, Mitchell JS, Martinov T, Burbach BJ, et al
    Adoptive T Cell Therapy with IL-12-Preconditioned Low-Avidity T Cells Prevents Exhaustion and Results in Enhanced T Cell Activation, Enhanced Tumor Clearance, and Decreased Risk for Autoimmunity.
    J Immunol. 2020 Jul 31. pii: jimmunol.2000007. doi: 10.4049/jimmunol.2000007.
    PubMed     Abstract available

    April 2020
  5. WILSKI NA, Stotesbury C, Del Casale C, Montoya B, et al
    STING Sensing of Murine Cytomegalovirus Alters the Tumor Microenvironment to Promote Antitumor Immunity.
    J Immunol. 2020 Apr 13. pii: jimmunol.1901136. doi: 10.4049/jimmunol.1901136.
    PubMed     Abstract available

  6. RAUSCH MP, Meador LR, Metzger TC, Li H, et al
    GILT in Thymic Epithelial Cells Facilitates Central CD4 T Cell Tolerance to a Tissue-Restricted, Melanoma-Associated Self-Antigen.
    J Immunol. 2020 Apr 8. pii: jimmunol.1900523. doi: 10.4049/jimmunol.1900523.
    PubMed     Abstract available

    February 2020
  7. RAMIREZ-MORENO IG, Ibarra-Sanchez A, Castillo-Arellano JI, Blank U, et al
    Mast Cells Localize in Hypoxic Zones of Tumors and Secrete CCL-2 under Hypoxia through Activation of L-Type Calcium Channels.
    J Immunol. 2020;204:1056-1068.
    PubMed     Abstract available

    January 2020
  8. BALLY APR, Neeld DK, Lu P, Majumder P, et al
    PD-1 Expression during Acute Infection Is Repressed through an LSD1-Blimp-1 Axis.
    J Immunol. 2020;204:449-458.
    PubMed     Abstract available

    October 2019
  9. BUETOW KH, Meador LR, Menon H, Lu YK, et al
    High GILT Expression and an Active and Intact MHC Class II Antigen Presentation Pathway Are Associated with Improved Survival in Melanoma.
    J Immunol. 2019 Oct 7. pii: jimmunol.1900476. doi: 10.4049/jimmunol.1900476.
    PubMed     Abstract available

    June 2019
  10. GANDHAPUDI SK, Ward M, Bush JPC, Bedu-Addo F, et al
    Antigen Priming with Enantiospecific Cationic Lipid Nanoparticles Induces Potent Antitumor CTL Responses through Novel Induction of a Type I IFN Response.
    J Immunol. 2019;202:3524-3536.
    PubMed     Abstract available

  11. DANAHY DB, Kurup SP, Winborn CS, Jensen IJ, et al
    Sepsis-Induced State of Immunoparalysis Is Defined by Diminished CD8 T Cell-Mediated Antitumor Immunity.
    J Immunol. 2019 Jun 12. pii: jimmunol.1900435. doi: 10.4049/jimmunol.1900435.
    PubMed     Abstract available

    April 2019
  12. DANAHY DB, Jensen IJ, Griffith TS, Badovinac VP, et al
    Cutting Edge: Polymicrobial Sepsis Has the Capacity to Reinvigorate Tumor-Infiltrating CD8 T Cells and Prolong Host Survival.
    J Immunol. 2019 Apr 10. pii: jimmunol.1900076. doi: 10.4049/jimmunol.1900076.
    PubMed     Abstract available

    February 2019
  13. ERIKSSON E, Milenova I, Wenthe J, Moreno R, et al
    IL-6 Signaling Blockade during CD40-Mediated Immune Activation Favors Antitumor Factors by Reducing TGF-beta, Collagen Type I, and PD-L1/PD-1.
    J Immunol. 2019;202:787-798.
    PubMed     Abstract available

  14. SALERNO F, Freen-van Heeren JJ, Guislain A, Nicolet BP, et al
    Costimulation through TLR2 Drives Polyfunctional CD8(+) T Cell Responses.
    J Immunol. 2019;202:714-723.
    PubMed     Abstract available

  15. LEE CC, Ding X, Zhao T, Wu L, et al
    Transthyretin Stimulates Tumor Growth through Regulation of Tumor, Immune, and Endothelial Cells.
    J Immunol. 2019;202:991-1002.
    PubMed     Abstract available

    September 2018
  16. BADAMCHI-ZADEH A, Moynihan KD, Larocca RA, Aid M, et al
    Combined HDAC and BET Inhibition Enhances Melanoma Vaccine Immunogenicity and Efficacy.
    J Immunol. 2018 Sep 24. pii: jimmunol.1800885. doi: 10.4049/jimmunol.1800885.
    PubMed     Abstract available

    August 2018
  17. VIGNERON N, Ferrari V, Van den Eynde BJ, Cresswell P, et al
    Cytosolic Processing Governs TAP-Independent Presentation of a Critical Melanoma Antigen.
    J Immunol. 2018 Aug 22. pii: jimmunol.1701479. doi: 10.4049/jimmunol.1701479.
    PubMed     Abstract available

    April 2018
  18. GILFILLAN CB, Kuhn S, Baey C, Hyde EJ, et al
    Clec9A(+) Dendritic Cells Are Not Essential for Antitumor CD8(+) T Cell Responses Induced by Poly I:C Immunotherapy.
    J Immunol. 2018;200:2978-2986.
    PubMed     Abstract available

  19. RIUS C, Attaf M, Tungatt K, Bianchi V, et al
    Peptide-MHC Class I Tetramers Can Fail To Detect Relevant Functional T Cell Clonotypes and Underestimate Antigen-Reactive T Cell Populations.
    J Immunol. 2018;200:2263-2279.
    PubMed     Abstract available

    March 2018
  20. GODING SR, Wilson KA, Rosinsky C, Antony PA, et al
    PD-L1-Independent Mechanisms Control the Resistance of Melanoma to CD4(+) T Cell Adoptive Immunotherapy.
    J Immunol. 2018 Mar 30. pii: jimmunol.1701617. doi: 10.4049/jimmunol.1701617.
    PubMed     Abstract available

    February 2018
  21. MITTAL P, Abblett R, Ryan JM, Hagymasi AT, et al
    An Immunotherapeutic CD137 Agonist Releases Eomesodermin from ThPOK Repression in CD4 T Cells.
    J Immunol. 2018;200:1513-1526.
    PubMed     Abstract available

    October 2017
  22. DING Q, Mohib K, Kuchroo VK, Rothstein DM, et al
    TIM-4 Identifies IFN-gamma-Expressing Proinflammatory B Effector 1 Cells That Promote Tumor and Allograft Rejection.
    J Immunol. 2017;199:2585-2595.
    PubMed     Abstract available

    May 2017
  23. ZILIO S, Vella JL, De la Fuente AC, Daftarian PM, et al
    4PD Functionalized Dendrimers: A Flexible Tool for In Vivo Gene Silencing of Tumor-Educated Myeloid Cells.
    J Immunol. 2017;198:4166-4177.
    PubMed     Abstract available

    February 2017
  24. ERKES DA, Smith CJ, Wilski NA, Caldeira-Dantas S, et al
    Virus-Specific CD8+ T Cells Infiltrate Melanoma Lesions and Retain Function Independently of PD-1 Expression.
    J Immunol. 2017 Feb 15. pii: 1601064. doi: 10.4049/jimmunol.1601064.
    PubMed     Abstract available

    January 2017
  25. RAKHMILEVICH AL, Felder M, Lever L, Slowinski J, et al
    Effective Combination of Innate and Adaptive Immunotherapeutic Approaches in a Mouse Melanoma Model.
    J Immunol. 2017 Jan 6. pii: 1601255. doi: 10.4049/jimmunol.1601255.
    PubMed     Abstract available

  26. BALLY AP, Tang Y, Lee JT, Barwick BG, et al
    Conserved Region C Functions To Regulate PD-1 Expression and Subsequent CD8 T Cell Memory.
    J Immunol. 2017;198:205-217.
    PubMed     Abstract available

    December 2016
  27. NASTI TH, Cochran JB, Vachhani RV, McKay K, et al
    IL-23 Inhibits Melanoma Development by Augmenting DNA Repair and Modulating T Cell Subpopulations.
    J Immunol. 2016 Dec 21. pii: 1601455. doi: 10.4049/jimmunol.1601455.
    PubMed     Abstract available

  28. WISTUBA-HAMPRECHT K, Martens A, Weide B, Teng KW, et al
    Establishing High Dimensional Immune Signatures from Peripheral Blood via Mass Cytometry in a Discovery Cohort of Stage IV Melanoma Patients.
    J Immunol. 2016 Dec 16. pii: 1600875.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.